Tenofovir toxicity: association with Inosine Triphosphate Pyrophosphohydrolase activity and ITPA genotype

Completed

• Conditions: Bijwerkingen medicatie; Inosine triphosphate pyrophosphohydrolase deficiency; 10047438

• Registration Number: NL-OMON45178
• Lead Sponsor: Inwendige geneeskunde, Sectie Infectieziekten

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 100

Inclusion Criteria

HIV-infected patients, aged over 18 years, who were or are still being treated with a anti-retroviral treatment containing tenofovir.

Exclusion Criteria

Not applicable

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Association between ITPase activity and nephrotoxicity, bone toxicity and<br /><br>recovery of nephrotoxicity and bone toxicity during and after tenofovir<br /><br>containing antiretroviral treatment for HIV.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Association between ITPA genotype and nephrotoxicity, bone toxicity and<br /><br>recovery of nephrotoxicity and bone toxicity during and after tenofovir<br /><br>containing antiretroviral treatment for HIV.</p><br>